Roche Kapitalmarkt AG Basel, founded in Basel, Switzerland, serves as the capital markets arm of the Roche Group, which is primarily focused on pharmaceuticals and diagnostics. The company is dedicated to managing the financing needs of Roche through innovative financial solutions, including bond issuances and treasury management services.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| ROSW 0.25% 2025-09-24 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2025-09-24 | 0.250 | -0.40 |
| ROSW 0.45% 2029-03-23 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2029-03-23 | 0.450 | 0.41 |
| ROSW 0.50% 2027-02-25 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2027-02-25 | 0.500 | 0.24 |
| ROSW 0.75% 2030-09-24 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2030-09-24 | 0.750 | 0.56 |
| ROSW 0.75% 2031-02-25 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2031-02-25 | 0.750 | 0.60 |
| ROSW 1.00% 2037-02-25 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2037-02-25 | 1.000 | 1.02 |
| ROSW 1.50% 2026-06-23 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2026-06-23 | 1.500 | 0.16 |
| ROSW 1.60% 2028-09-15 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2028-09-15 | 1.600 | 0.43 |
| ROSW 1.75% 2033-09-15 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2033-09-15 | 1.750 | 0.89 |
| ROSW 1.95% 2038-09-15 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2038-09-15 | 1.950 | 1.21 |
| ROSW 2.00% 2032-09-23 CHFRoche Kapitalmarkt AG Basel | Switzerland | 2032-09-23 | 2.000 | 0.71 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Roche Kapitalmarkt AG has a notable history of bond issuance, having launched its first bonds in 2009, which aimed to support strategic corporate initiatives. The company has since established itself in the market, with significant issuances including a €1 billion bond in 2021 that was well-received amid low-interest rates, highlighting its strong standing in financial markets. Current yields on Roche's bonds remain competitive, reflecting a solid credit rating and investor confidence, while notable features of its bonds include green bond offerings that align with Roche’s sustainability goals.